Fjarde AP Fonden Fourth Swedish National Pension Fund Has $22.95 Million Stock Holdings in Pfizer Inc. $PFE

Fjarde AP Fonden Fourth Swedish National Pension Fund trimmed its holdings in Pfizer Inc. (NYSE:PFE) by 9.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 921,771 shares of the biopharmaceutical company’s stock after selling 92,200 shares during the quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Pfizer were worth $22,952,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Arsenal Capital Advisors LLC acquired a new position in shares of Pfizer in the 4th quarter valued at about $244,000. Flagship Wealth Advisors LLC increased its position in Pfizer by 3.4% in the 4th quarter. Flagship Wealth Advisors LLC now owns 14,311 shares of the biopharmaceutical company’s stock valued at $356,000 after buying an additional 474 shares in the last quarter. Prestige Wealth Management Group LLC increased its position in Pfizer by 196.5% in the 4th quarter. Prestige Wealth Management Group LLC now owns 23,116 shares of the biopharmaceutical company’s stock valued at $576,000 after buying an additional 15,319 shares in the last quarter. Deseret Mutual Benefit Administrators increased its position in Pfizer by 4.7% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 49,306 shares of the biopharmaceutical company’s stock valued at $1,228,000 after buying an additional 2,193 shares in the last quarter. Finally, Curio Wealth LLC increased its position in Pfizer by 51.4% in the 4th quarter. Curio Wealth LLC now owns 1,637 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 556 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts recently commented on PFE shares. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Daiwa Securities Group lowered Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a research report on Thursday, February 12th. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of Pfizer in a research report on Monday. Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 24th. Finally, Argus raised Pfizer from a “hold” rating to a “buy” rating and set a $35.00 target price for the company in a research report on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, eleven have issued a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $28.82.

Pfizer Stock Performance

Shares of PFE opened at $26.04 on Friday. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25. The stock has a 50 day moving average price of $26.62 and a two-hundred day moving average price of $26.29. The firm has a market capitalization of $148.43 billion, a P/E ratio of 19.88 and a beta of 0.34. Pfizer Inc. has a 52 week low of $23.11 and a 52 week high of $28.75.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The company had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same period last year, the firm earned $0.92 earnings per share. The firm’s revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio (DPR) is presently 131.30%.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer signed a license agreement with Chai Discovery to gain early access to its AI drug-discovery platform, including the new Chai-3 model, which could improve antibody design and speed up research productivity. Pfizer signs licence agreement with Chai for AI drug discovery
• Positive Sentiment: Pfizer also reported fresh clinical-trial progress across its oncology pipeline, including updates on a lung cancer study, a bladder cancer combination trial with Astellas, and another advanced lung cancer combination program, signaling continued investment in future growth drivers. Pfizer’s New Lung Cancer Study Signals Fresh Oncology Upside for PFE Investors
• Positive Sentiment: Pfizer disclosed an update on a Phase 3 infant pneumococcal vaccine trial, suggesting continued momentum in its vaccine franchise and potential additional data catalysts ahead. Pfizer’s New Infant Pneumococcal Vaccine Trial: What Investors Should Watch
• Neutral Sentiment: Pfizer’s recent conference presentation and multiple earnings-related recap articles did not introduce a major new financial surprise, but they kept attention on post-earnings expectations and the company’s valuation. Pfizer Inc. (PFE) Presents at Jefferies Global Healthcare Conference 2026 Transcript
• Negative Sentiment: Some market commentary continues to highlight that PFE has been under pressure since its last earnings report, reflecting investor caution around near-term growth and execution. Why Is Pfizer (PFE) Down 4.5% Since Last Earnings Report?

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.